Autobahn Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$101M
- Investors
-
18
Autobahn Therapeutics General Information
Description
Developer of regenerative medicines and brain-targeting therapeutics intended for restoring the hopes of people affected by central nervous system disorders. The company's medicines are focused on high unmet need areas of neuropsychiatry, neurodegeneration and neuroinflammation with aims to unlock new therapeutic opportunities through precision tuning of CNS(Central nervous system) exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers, enabling patients with major depressive disorder and bipolar disorder depression to live the futures they deserve.
Contact Information
Website
www.autobahntx.comCorporate Office
- 9880 Campus Point Drive
- Suite 370
- San Diego, CA 92121
- United States
Corporate Office
- 9880 Campus Point Drive
- Suite 370
- San Diego, CA 92121
- United States
Autobahn Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 24-Jul-2024 | $101M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series B) | 08-Sep-2022 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 09-Jun-2020 | $75.9M | $80.9M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A1) | 22-Mar-2018 | $5M | $5M | Completed | Startup |
Autobahn Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 20,971,271 | $0.000100 | 6% | $0.87 | $0.87 | 1x | $0.87 | 5.85% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Autobahn Therapeutics Comparisons
Industry
Financing
Details
Autobahn Therapeutics Competitors (56)
One of Autobahn Therapeutics’s 56 competitors is Neurelis, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neurelis | Venture Capital-Backed | San Diego, CA | ||||
| Clexio Biosciences | Corporation | Jerusalem, Israel | ||||
| Neumora | Formerly VC-backed | Watertown, MA | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Xenon Pharmaceuticals | Formerly VC-backed | Burnaby, Canada |
Autobahn Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Autobahn Therapeutics Patents
Autobahn Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025090792-A1 | Amide prodrugs and uses thereof | Inactive | 27-Oct-2023 | ||
| WO-2025090793-A1 | Amide prodrugs and uses thereof | Inactive | 27-Oct-2023 | ||
| AU-2024331485-A1 | Amide prodrugs and uses thereof | Pending | 31-Aug-2023 | ||
| EP-4770991-A1 | Amide prodrugs and uses thereof | Pending | 31-Aug-2023 | ||
| WO-2025049767-A1 | Amide prodrugs and uses thereof | Inactive | 31-Aug-2023 | C07D205/04 |
Autobahn Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Autobahn Therapeutics Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Blue Owl Capital | Asset Manager | Minority | ||
| Canaan Partners | Venture Capital | Minority | ||
| Insight Partners (New York) | PE/Buyout | Minority | ||
| Leerink Partners | Investment Bank | Minority | ||
| Monograph Capital | Venture Capital | Minority |
Autobahn Therapeutics Investments (1)
Autobahn Therapeutics’s most recent deal was a Corporate Asset Purchase with Astellas (ASP3652). The deal was made on 11-May-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Astellas (ASP3652) | 11-May-2021 | Corporate Asset Purchase | Buildings and Property |
Autobahn Therapeutics FAQs
-
When was Autobahn Therapeutics founded?
Autobahn Therapeutics was founded in 2017.
-
Where is Autobahn Therapeutics headquartered?
Autobahn Therapeutics is headquartered in San Diego, CA.
-
What is the size of Autobahn Therapeutics?
Autobahn Therapeutics has 35 total employees.
-
What industry is Autobahn Therapeutics in?
Autobahn Therapeutics’s primary industry is Biotechnology.
-
Is Autobahn Therapeutics a private or public company?
Autobahn Therapeutics is a Private company.
-
What is the current valuation of Autobahn Therapeutics?
The current valuation of Autobahn Therapeutics is .
-
What is Autobahn Therapeutics’s current revenue?
The current revenue for Autobahn Therapeutics is .
-
How much funding has Autobahn Therapeutics raised over time?
Autobahn Therapeutics has raised $214M.
-
Who are Autobahn Therapeutics’s investors?
Blue Owl Capital, Canaan Partners, Insight Partners (New York), Leerink Partners, and Monograph Capital are 5 of 18 investors who have invested in Autobahn Therapeutics.
-
Who are Autobahn Therapeutics’s competitors?
Neurelis, Clexio Biosciences, Neumora, Neurona Therapeutics, and Xenon Pharmaceuticals are some of the 56 competitors of Autobahn Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
